Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

Kluetz, Paul G., Pierce, William, Maher, V. Ellen, Zhang, Hui, Tang, Shenghui, Song, Pengfei, Liu, Qi, Haber, Martin T., Leutzinger, Eldon E., Al-Hakim, Ali, Chen, Wei, Palmby, Todd, Alebachew, Elleni, Sridhara, Rajeshwari, Ibrahim, Amna, Justice, Robert, Pazdur, Richard · 2014 · Clinical Cancer Research

Abstract

On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Ra-223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. The FDA review was based on clinical trial BC1-06, which randomly allocated patients (2:1) to either Ra-223 plus best standard of care (BSoC) or placebo plus BSoC. The primary endpoint was overall survival (OS) with a key secondary endpoint of time to first symptomatic skeletal event (SSE). A statistically significant improvement in OS was demonstrated [HR, 0.70; 95% confidence interval, 0.55–0.88, P = 0.0019]. At the prespecified interim analysis, the median OS durations were 14.0 and 11.2 months in the Ra-223 and placebo arms, respectively. The improvement in OS was supported by a delay in time to first SSE favoring the Ra-223 arm. The most common (>10%) adverse reactions in patients receiving Ra-223 were nausea, diarrhea, vomiting, and peripheral edema. The most common (>10%) hematologic laboratory abnormalities were anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia. Ra-223 is the first α-emitting radiotherapeutic and the first radiopharmaceutical to demonstrate an OS advantage in metastatic prostate cancer. Clin Cancer Res; 20(1); 9–14. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-2665

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 170

Metadata

Authors
Kluetz, P. G., Pierce, W., Maher, V. E., Zhang, H., Tang, S., Song, P., Liu, Q., Haber, M. T., Leutzinger, E. E., Al-Hakim, A., Chen, W., Palmby, T., Alebachew, E., Sridhara, R., Ibrahim, A., Justice, R., & Pazdur, R.
Venue
Clinical Cancer Research
Published
2014-01-01
Volume
20
Issue
1
Pages
9-14
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2022687463
Cited by
170
References
4
FWCI
7.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2665
The paper
Kluetz, P. G., Pierce, W., Maher, V. E., Zhang, H., Tang, S., Song, P., Liu, Q., Haber, M. T., Leutzinger, E. E., Al-Hakim, A., Chen, W., Palmby, T., Alebachew, E., Sridhara, R., Ibrahim, A., Justice, R., & Pazdur, R. (2014). Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2665

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.